Thomas N O'Connor

6PUBLICATIONS
20CO-AUTHORS
Cancer geneticsMolecular targetsBiomaterialsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 16, 2026
Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.

|Jan 23, 2026
Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Thomas N O'Connor, Emily Schultz, Sheheryar Kabraji

|Sep 13, 2025
Voluntary Wheel Running Mitigates Disease in an Orai1 Gain-of-Function Mouse Model of Tubular Aggregate Myopathy.

Thomas N O'Connor, Nan Zhao, Haley M Orciuoli

|Feb 13, 2025
Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222.

Adam P Dommer, Vishnu Kumarasamy, Jianxin Wang

|Aug 16, 2024
Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models.

Jin Wu, Jianxin Wang, Thomas N O'Connor

|May 11, 2024
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy.

Thomas N O'Connor, Emily Schultz, Jianxin Wang

Pageof 1

Frequent Collaborators

4 joint publications

Erik S Knudsen

3 joint publications

Emily Schultz

2 joint publications

Ellis Levine

2 joint publications

Jianxin Wang